HC Wainwright Reaffirms Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)

HC Wainwright reiterated their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) in a research report released on Monday, Benzinga reports. The brokerage currently has a $100.00 price objective on the stock.

A number of other analysts have also commented on MLTX. Oppenheimer started coverage on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 25th. They set an outperform rating and a $104.00 target price for the company. The Goldman Sachs Group began coverage on shares of MoonLake Immunotherapeutics in a research report on Tuesday, April 2nd. They issued a neutral rating and a $62.00 price objective on the stock. Needham & Company LLC reissued a buy rating and issued a $66.00 price objective on shares of MoonLake Immunotherapeutics in a report on Monday, June 10th. Finally, Wedbush restated an outperform rating and issued a $92.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Wednesday, March 13th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $79.00.

MoonLake Immunotherapeutics Stock Up 5.1 %

NASDAQ:MLTX opened at $42.20 on Monday. The firm has a 50-day moving average price of $41.35 and a 200 day moving average price of $49.04. The firm has a market capitalization of $2.70 billion, a PE ratio of -56.27 and a beta of 1.25. MoonLake Immunotherapeutics has a 12-month low of $35.11 and a 12-month high of $64.98.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Sunday, May 12th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, research analysts expect that MoonLake Immunotherapeutics will post -1.21 EPS for the current year.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of large investors have recently bought and sold shares of MLTX. Avoro Capital Advisors LLC grew its position in MoonLake Immunotherapeutics by 29.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,580,000 shares of the company’s stock worth $155,806,000 after acquiring an additional 580,001 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in MoonLake Immunotherapeutics by 9.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,314,012 shares of the company’s stock valued at $139,744,000 after purchasing an additional 196,144 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of MoonLake Immunotherapeutics by 42.3% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,952,703 shares of the company’s stock worth $111,304,000 after acquiring an additional 580,375 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in shares of MoonLake Immunotherapeutics by 48.8% during the first quarter. Westfield Capital Management Co. LP now owns 910,873 shares of the company’s stock valued at $45,753,000 after buying an additional 298,823 shares during the last quarter. Finally, Finepoint Capital LP grew its stake in shares of MoonLake Immunotherapeutics by 170.1% in the 4th quarter. Finepoint Capital LP now owns 895,000 shares of the company’s stock worth $54,049,000 after acquiring an additional 563,584 shares in the last quarter. 93.85% of the stock is currently owned by institutional investors and hedge funds.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.